Cargando…
Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study
The aim of this study was to evaluate the prognostic impact of FLT3-ITD in core-binding factor acute myeloid leukemia (CBFAML) in an international, multicenter survey of 97 patients of whom 52% had t(8;21)(q22;q22) and 48% had inv(16)(p13q22)/t(16;16)(p13;q22). The median age of the patients was 53...
Autores principales: | Kayser, Sabine, Kramer, Michael, Martínez-Cuadrón, David, Grenet, Justin, Metzeler, Klaus H., Sustkova, Zuzana, Luskin, Marlise R., Brunner, Andrew M., Elliott, Michelle A., Gil, Cristina, Marini, Sandra Casal, Ráčil, Zdeněk, Cetkovsky, Petr, Novak, Jan, Perl, Alexander E., Platzbecker, Uwe, Stölzel, Friedrich, Ho, Anthony D., Thiede, Christian, Stone, Richard M., Röllig, Christoph, Montesinos, Pau, Schlenk, Richard F., Levis, Mark J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968900/ https://www.ncbi.nlm.nih.gov/pubmed/34348451 http://dx.doi.org/10.3324/haematol.2021.278645 |
Ejemplares similares
-
Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports
por: Martínez-Cuadrón, David, et al.
Publicado: (2020) -
Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial
por: Ruhnke, Leo, et al.
Publicado: (2023) -
S137: IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN FIRST COMPLETE REMISSION PLUS FLT3 INHIBITION WITH QUIZARTINIB IN ACUTE MYELOID LEUKEMIA WITH FLT3-ITD: RESULTS FROM QUANTUM-FIRST
por: Schlenk, Richard, et al.
Publicado: (2023) -
P483: QUANTUM-FIRST TRIAL: FLT3-ITD–SPECIFIC MEASURABLE RESIDUAL DISEASE (MRD) CLEARANCE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL
por: Levis, Mark J, et al.
Publicado: (2023) -
FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years
por: Shimony, Shai, et al.
Publicado: (2023)